Nutriband Inc. Announces 25% Preferred Stock Dividend Tied to AVERSA Fentanyl FDA Approval
July 2nd, 2025 1:48 PM
By: Newsworthy Staff
Nutriband Inc. has approved a 25% preferred stock dividend, linking shareholder benefits directly to the FDA approval of its AVERSA Fentanyl product, underscoring the company's progress in developing abuse-deterrent pharmaceutical technologies.
Nutriband Inc. (NASDAQ: NTRB) has announced a significant move for its shareholders, approving a 25% preferred stock dividend. This decision grants one preferred share for every four common shares held by investors as of July 25, 2025, with the distribution scheduled for August 5. The unique aspect of this dividend is its linkage to the FDA approval of the company's AVERSA Fentanyl product, with each preferred share convertible to one common share upon approval. In the absence of conversion, these preferred shares will be eligible for annual cash dividends, contingent on company profits and the Board's discretion. CEO Gareth Sheridan highlighted this strategy as a reflection of Nutriband's dedication to enhancing shareholder value amidst its strides toward commercializing AVERSA. For further details, visit https://ibn.fm/4dkCf.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
